Skip to main content
Fig. 2 | BMC Pulmonary Medicine

Fig. 2

From: Effectiveness of the Polish program for the treatment of severe allergic asthma with omalizumab: a single-center experience

Fig. 2

Changes in asthma control questionnaire (ACQ) scores, asthma quality of life questionnaire (AQLQ) scores, systemic corticosteroid (SCS) use, and forced expiratory volume in one second (FEV1) after 16 weeks of omalizumab (OMA) treatment in 16 evaluated patients in the cohort. Dashed lines indicate the cut off for a clinically significance difference

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us